Login
Home / CARM : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Carisma Therapeutics, Inc.

$0 -$0.04 (-98.18%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0.39
Market Cap
33.48K
AVG Volume
24.24K
Trailing/Forward PE
0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
2026-11-05
Primary Exchange
Other OTCUS
Revenue (USD)
020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Net Income (USD)
-40M-20M020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Operating Income (USD)
-40M-20M020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
EBITDA (USD)
-40M-20M020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Cash Flows (USD)
-30M-20M-10M010M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
EPS (USD)
-1-0.500.511.523 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Expenses (USD)
010M20M30MR&DSG&ACapex23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Cash & Debt (USD)
050M100M150MCashLong Term DebtShort Term Debt23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Debt ratios
-0.500.511.5223 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Margins
-600%-400%-200%0%200%23 Q123 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q3
Return on Capital
-6000%-4000%-2000%0%2000%23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Shares Outstanding
020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Dividends (USD)
00.511.5Mar 23
Employee Count
05010015020232024
Book Value Per Share (USD)
-2-101223 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Total Assets (USD)
050M100M150M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
PE Ratio
0200400600800med 0.25Apr 17Jul 17Oct 17Jan 26Mar 26Jun 26Sep 26
Free Cash Flow Yield
-600000%-400000%-200000%0%med -755.1%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
0123med 0.39Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
-25002505007501000med -0Apr 17Jul 17Oct 17Jan 26Mar 26Jun 26Sep 26
Price/Operating Cashflow
0100200300400500med 121.18Apr 17May 17Jun 17Jul 17Sep 17Oct 17Nov 17
Price to Book
050100150med 4.38Mar 22Jul 22Sep 23Dec 23Apr 24Jul 24Nov 24
Carisma Therapeutics, Inc.
CARM
Stockpicker

Video analysis: CARM

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CARM

Carmila: 2026 H1 Results

businesswire.com · 29 Jul 2026

Carmila: 2026 H1 Results

PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): 2026 EPS1 guidance raised to €1.87 (from €1.84, vs €1.81 in 2025) Now expecting 3.3% EPS growth in 2026 Guidance upgrade driven by operating performance and Dijon Grand Quetigny acquisition Strong momentum across the three growth engines powered by asset transformation Organic growth: net rental income +1.4% (100 bps above indexation, continuing consistent outperformance) as restructuring and remerchandising have unlocked record ten.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.